Pharvaris (PHVS) AI Stock Analysis

• Market Cap: $1.00B
• Dividend Yield: N/A
• Average Volume (3M): 78.28K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.93
• Revenue Growth: N/A
• EPS Growth: 0.71%
• Country: US
• Employees: 108
• Sector: Healthcare
• Sector Strength: 56
• Industry: Biotechnology
• EPS (TTM): -2.69
• Shares Outstanding: 54,493,140
• 10 Day Avg. Volume: 175,437
• 30 Day Avg. Volume: 78,285
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $33.67
• Price Target Upside: 83.29% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

Pharvaris exhibits significant financial difficulties, with no revenue and ongoing losses, resulting in a low financial performance score. Despite some technical momentum, the valuation is poor due to negative earnings. The stock's overall score is affected by these financial and valuation challenges, despite its technical strength.

Positive Factors

Drug Efficacy

Deucrictibant's Phase 2 data look stronger than the only approved oral HAE long-term prophylaxis therapy, Orladeyo.

Financial Stability

The company has a strong cash position with €281 in equivalents, providing financial stability through pivotal readouts.

Market Potential

Deucrictibant could compete for market share in two seemingly independent buckets of HAE patients.

Negative Factors

Clinical Risks

Investment thesis continues to be primarily driven by the prophy program, which still needs significant de-risking given this would be the first study using the XR formulation and efficacy is commonly reduced when moving from a phase 2 to a phase 3 study.

Financial Performance

PHVS reported a net loss of €34.8M, or €(0.64) per share.

Market Competition

HAE treatment markets are becoming increasingly crowded with multiple approved therapies and several clinical competitors.

Pharvaris Business Overview & Revenue Model

Company Description

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

How the Company Makes Money

Pharvaris makes money by developing and commercializing oral therapies, primarily focusing on hereditary angioedema (HAE). As a clinical-stage company, its revenue model is dependent on advancing its drug candidates through clinical trials and eventually obtaining regulatory approval for commercial sale. Revenue streams are expected to come from potential future sales of approved therapies, licensing agreements, and partnerships with other pharmaceutical companies. Significant partnerships could involve collaboration on research and development, co-marketing, or distribution agreements that enhance the company's ability to bring its therapies to market.

Pharvaris Financial Statement Overview

Summary

Overall, Pharvaris faces significant financial challenges with no revenue generation and ongoing losses impacting income statements. The strong equity position provides some balance sheet stability, yet cash flow concerns remain due to negative operating and free cash flow, despite substantial financing inflows. The lack of revenue growth and profitability highlights the risks associated with the company's financial health.

Income Statement

Pharvaris has consistently shown no revenue generation over the years, leading to a lack of gross profit and persistent net losses. The company's net profit margin is nonexistent due to zero revenue, and the EBIT margin indicates significant operational losses. The financials reflect a challenging position in terms of profitability and revenue growth.

Balance Sheet

The balance sheet reveals a strong equity position with a high equity ratio, indicating stability and low financial leverage. The debt-to-equity ratio is minimal, suggesting limited reliance on debt. However, the company is not yet profitable, which poses a risk to long-term sustainability despite the strong equity base.

Cash Flow

Pharvaris has been experiencing negative free cash flow and operating cash flow, reflecting cash outflows that exceed inflows. The cash flow to net income ratios are not favorable due to persistent losses, indicating cash burn concerns. However, significant financing activities have bolstered cash reserves, providing some liquidity cushion.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
-252.27K	-150.19K	-80.46K	0.00	―
	EBIT
-96.91M	-86.74M	-65.90M	-25.01M	-7.99M
	EBITDA
-96.85M	-86.58M	-54.06M	-25.01M	-8.01M
	Net Income Common Stockholders
-100.88M	-76.33M	-42.73M	-25.99M	-8.04M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
391.23M	161.84M	209.35M	98.63M	20.33M
	Total Assets
398.69M	167.73M	212.09M	101.10M	20.60M
	Total Debt
238.91K	436.82K	250.18K	0.00	0.00
	Net Debt
-390.99M	-161.40M	-209.10M	-98.63M	-20.33M
	Total Liabilities
14.65M	18.47M	7.14M	5.31M	1.92M
	Stockholders Equity
384.05M	149.26M	204.95M	95.79M	18.67M
Cash Flow		Free Cash Flow
-93.14M	-67.29M	-44.73M	-21.54M	-6.69M
	Operating Cash Flow
-93.05M	-67.16M	-44.60M	-21.50M	-6.68M
	Investing Cash Flow
-89.98K	-124.30K	-130.03K	-42.98K	-13.48K
	Financing Cash Flow
325.39M	8.65M	143.67M	101.20M	21.63M

Pharvaris Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 18.37
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHVS, the sentiment is Positive. The current price of 18.37 is above the 20-day moving average (MA) of 15.01, above the 50-day MA of 15.33, and above the 200-day MA of 18.22, indicating a bullish trend. The MACD of 0.94 indicates Negative momentum. The RSI at 70.22 is Negative, neither overbought nor oversold. The STOCH value of 88.39 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PHVS.

Pharvaris Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CVAC	74 Outperform	$801.55M	4.39	28.12%	―	910.33%	―
XERS	52 Neutral	$725.06M	―	222.83%	―	23.89%	16.86%
Sector *	52 Neutral	$5.35B	3.81	-42.57%	2.86%	17.10%	1.33%
ABCL	49 Neutral	$718.15M	―	-14.75%	―	-24.17%	-9.24%
ZYME	48 Neutral	$909.11M	―	-30.54%	―	0.38%	6.94%
PHVS	42 Neutral	$1.00B	―	-41.43%	―	―	0.71%
XNCR	41 Neutral	$801.17M	―	-34.74%	―	-36.72%	-64.37%